Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT06550076

PHASE3

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Sponsor: Takeda

View on ClinicalTrials.gov

Summary

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.

Official title: A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1950

Start Date

2024-09-04

Completion Date

2026-05-07

Last Updated

2026-01-15

Healthy Volunteers

Conditions

Plaque Psoriasis

Interventions

DRUG

TAK-279

TAK-279 oral tablet

Main Inclusion Criteria: Part A: * Participant is willing and able to understand and fully comply with study procedures and requirements (including digital tools and applications), in the opinion of the investigator. * Participant has provided written informed consent and any required privacy authorization before the initiation of any study procedures. * Participant is aged 18 years or older at the time of consent. * Participant has a diagnosis of chronic plaque psoriasis for \>=6 months prior to the screening visit. * Participant has stable plaque psoriasis defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis for \>=6 months before screening. * Participant has moderate-to-severe plaque psoriasis as defined by a PASI score \>=12 and a sPGA score \>=3 at screening and Day 1. * Participant has plaque psoriasis covering \>=10% of his or her total BSA at screening and Day 1. * Participant must be a candidate for phototherapy or systemic therapy. Part B: \- Participant has completed 52 weeks of treatment (TAK-279-3001 or Part A) or 60 weeks of treatment (TAK-279-3002), or 16 weeks of treatment (TAK-279-PsO-3004) in their parent study. Main Exclusion Criteria Part A: * Participant has evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis). If a participant meets criteria for inclusion based on typical plaque psoriasis presentation, a limited amount of inverse psoriasis is not exclusionary. * Participant requires systemic treatment, other than nonsteroidal anti-inflammatory drugs, during the trial period for an immune-related disease (e.g., inflammatory bowel disease). * Participant has any clinically significant medical condition, evidence of an unstable clinical condition (e.g., cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or immunologic), or vital signs/physical/laboratory/ECG abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results. These include but are not limited to: 1. Participant has a history of known or suspected condition/illness that is consistent with compromised immunity, including but not limited to any identified congenital or acquired immunodeficiency; splenectomy. 2. Participant had a major surgery within 60 days prior to Day 1 or has a major surgery planned during the study. 3. Participant has unstable, poorly controlled, or severe hypertension at screening, confirmed by 2 repeat assessments. 4. Participant has a history of Class III or IV congestive heart failure as defined by New York Heart Association criteria. 5. Participant has a history of cancer or lymphoproliferative disease, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix. 6. For participants with asthma, chronic obstructive pulmonary disease, or other pulmonary illnesses, participant has been hospitalized in the past 3 months, has ever required intubation for treatment, currently requires oral corticosteroids, or has required more than 1 course of oral corticosteroids within 6 months prior to Day 1. 7. Participant has any of the following cardiovascular disease history: A new diagnosis of atrial fibrillation or an episode of atrial fibrillation with rapid ventricular response or other dysrhythmia, non-acute cardiac hospitalization (e.g., pacemaker implantation), pulmonary embolism, or deep venous thrombosis within the past 6 months prior to screening. Any history of cerebrovascular event, myocardial infarction, coronary stenting, or aortocoronary bypass surgery. If, however, the investigator determines there are no suitable treatment alternatives available for the participant and it has been at least 6 months since the occurrence of any such event, the participant may enroll. 8. Participant has ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if he or she participated in the study, in the opinion of the investigator. 9. Participant has significant/uncontrolled psychiatric illness, in the opinion of the investigator. 10. Participant has any lifetime history of suicidal ideation, suicidal behavior, or suicidal attempts by 1) medical history; or 2) by Columbia-Suicide Severity Rating Scale (C-SSRS) documentation at screening or by answering "yes" to Question 5 for suicidal ideation on the C-SSRS at screening; or 3) is clinically deemed to have a suicide risk by the investigator. 11. Participant has a patient health questionnaire - 8 (PHQ-8) score of 15 or above at screening. 12. Participant has a history of clinically significant drug or alcohol abuse within 12 months prior to Day 1. * Participant has received any of the following biologics or biosimilar versions within the time frame indicated or 5 half-lives, whichever is longer: 1. Antibodies to interleukin (IL) -12/-23, IL-17, or IL-23 (eg, ustekinumab, secukinumab, tildrakizumab, ixekizumab, or guselkumab) within 6 months prior to Day 1. 2. Tumor necrosis factor inhibitor(s) (e.g., etanercept, adalimumab, infliximab, certolizumab) within 2 months prior to Day 1. 3. Agents that modulate integrin pathways to impact lymphocyte trafficking (e.g., natalizumab) or agents that modulate B cells or T cells (e.g., alemtuzumab, abatacept, or visilizumab) within 3 months prior to Day 1. 4. Rituximab or other immune cell-depleting therapy within 6 months prior to Day 1. * Participant has any previous exposure to TAK-279 (also known as NDI-034858) or other TYK2 inhibitors, including deucravacitinib, or participant participated in any study that included a TYK2 inhibitor (e.g., deucravacitinib, VTX958, GLPG3667, etc.), unless the participant has documentation of post-trial unblinding that confirms the partcipant did not receive a TYK2 inhibitor. * Participant has a known or suspected allergy to TAK-279 or any of its components. Part B: * Participant has completed the parent study or Part A but was permanently discontinued from treatment. * Participant had evidence of significant noncompliance with study visits or study drug in the parent study or Part A, as defined in the parent study protocol or in the opinion of the investigator. * Participant has met criteria for termination from the parent study or Part A, regardless of whether or not the participant was terminated from the parent study or Part A. * Participant has developed evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis) since enrollment in the parent study or Part A. * Participant has developed a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments. * Participant has received a prohibited psoriasis treatment during the parent study or Part A, whether or not that treatment was documented as a concomitant medication and is expected to continue that treatment.

Locations (278)

Total Dermatology

Birmingham, Alabama, United States

University of Alabama Hospital - Whitaker Clinic -

Birmingham, Alabama, United States

Cahaba Dermatology Skin Health Center

Hoover, Alabama, United States

Medical Dermatology Specialists

Phoenix, Arizona, United States

Saguaro Dermatology Associates, LLC - Probity - PPDS

Phoenix, Arizona, United States

Noble Clinical Research

Tucson, Arizona, United States

Johnson Dermatology Clinic

Fort Smith, Arkansas, United States

Burke Pharmaceutical Research

Hot Springs, Arkansas, United States

Zenith Research, Inc.

Beverly Hills, California, United States

First OC Dermatology Research Inc.

Fountain Valley, California, United States

Center for Dermatology Clinical Research

Fremont, California, United States

Long Beach Research Institute

Long Beach, California, United States

Metropolis Dermatology Downtown LA - Probity - PPDS

Los Angeles, California, United States

UCLA University of California Los Angeles

Los Angeles, California, United States

Northridge Clinical Trials

Northridge, California, United States

UC Davis Dermatology Clinic

Sacramento, California, United States

TCR Medical Corporation

San Diego, California, United States

University Clinical Trials

San Diego, California, United States

Dermatology Institute and Skin Care Center

Santa Monica, California, United States

UNISON Clinical Trials (Shahram Jacobs md inc.)

Sherman Oaks, California, United States

Driven Research LLC

Coral Gables, Florida, United States

Revival Research Corporation - Florida - ClinEdge - PPDS

Doral, Florida, United States

FXM Clinical Research Ft. Lauderdale, LLC

Fort Lauderdale, Florida, United States

Direct Helpers Medical Center

Hialeah, Florida, United States

Florida Academic Centers Research

Miami, Florida, United States

FXM Clinical Research Miami, LLC

Miami, Florida, United States

San Marcus Research Clinic Inc

Miami Lakes, Florida, United States

FXM Research Miramar

Miramar, Florida, United States

Renstar Medical Research -21 NE 1st Ave

Ocala, Florida, United States

Lenus Research & Medical Group

Sweetwater, Florida, United States

Advanced Clinical Research Institute (ACRI) - Florida

Tampa, Florida, United States

Divine Dermatology and Aesthetics, LLC

Atlanta, Georgia, United States

Marietta Dermatology & The Skin Cancer Center - Marietta

Marietta, Georgia, United States

Advanced Medical Research, PC

Sandy Springs, Georgia, United States

Georgia Skin and Cancer Clinic

Savannah, Georgia, United States

Leavitt Clinical Research

Idaho Falls, Idaho, United States

Arlington Dermatology

Rolling Meadows, Illinois, United States

NorthShore Medical Group Dermatology - Skokie

Skokie, Illinois, United States

DS Research - 1005 E. Lewis & Clark Pkwy Indiana Location

Clarksville, Indiana, United States

Dawes Fretzin Clinical Research Group, LLC

Indianapolis, Indiana, United States

Skin Sciences, PLLC

Louisville, Kentucky, United States

Dermatology Specialists Research - 3810 Springhurst Blvd

Louisville, Kentucky, United States

Lawrence J Green, MD LLC

Rockville, Maryland, United States

University of Michigan Hospital - 1500 E Medical Center Dr

Ann Arbor, Michigan, United States

Oakland Hills Dermatology - 3400 Auburn Rd

Auburn Hills, Michigan, United States

Revival Research Corporation - ClinEdge

Troy, Michigan, United States

Minnesota Clinical Study Center

New Brighton, Minnesota, United States

Skin Specialists PC

Omaha, Nebraska, United States

Henderson Clinical Trials

Henderson, Nevada, United States

Dartmouth Hitchcock Medical Center - Old Etna Rd

Lebanon, New Hampshire, United States

ALLCUTIS Research, LLC.

Portsmouth, New Hampshire, United States

Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey, United States

Sadick Research Group

New York, New York, United States

Montefiore AOA - BRANY

The Bronx, New York, United States

Accellacare of Cary

Cary, North Carolina, United States

The Skin Surgery Center for Clinical Research - Objective Health - PPDS

Winston-Salem, North Carolina, United States

Bexley Dermatology Research - Probity - PPDS

Bexley, Ohio, United States

Wright State Physicians

Fairborn, Ohio, United States

Apex Clinical Research Center

Mayfield Heights, Ohio, United States

Oregon Medical Research Center PC

Portland, Oregon, United States

University of Pittsburgh Medical Center-3601 5th Ave

Pittsburgh, Pennsylvania, United States

Cumberland Skin Center for Clinical Research - Objective Health - PPDS

Hermitage, Tennessee, United States

International Clinical Research US LLC

Murfreesboro, Tennessee, United States

Arlington Research Center

Arlington, Texas, United States

Bellaire Dermatology Associates

Bellaire, Texas, United States

UT Physicians Dermatology - Bellaire Station

Bellaire, Texas, United States

Modern Research Associates

Dallas, Texas, United States

North Texas Center for Clinical Research

Frisco, Texas, United States

San Antonio

San Antonio, Texas, United States

Texas Dermatology and Laser Specialists-San Antonio-7703 Floyd Curl Dr

San Antonio, Texas, United States

Dermatology Clinical Research Center of San Antonio

San Antonio, Texas, United States

Houston Center for Clinical Research, LLC

Sugar Land, Texas, United States

Center For Clinical Studies, LTD. LLP - 451 N Texas Ave

Webster, Texas, United States

Virginia Clinical Research - 6160 Kempsville Cir

Norfolk, Virginia, United States

Conexa Investigación Clínica S.A.

Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina

Centro de Investigaciones Médicas Tucumán

San Miguel de Tucumán, Tucumán Province, Argentina

Centro de Investigacion Clinica

Ciudad Autónomade Buenos Aires, Argentina

St George Dermatology and Skin Cancer Center - Probity - PPDS

Kogarah, New South Wales, Australia

The Skin Center - Probity

Benowa, Queensland, Australia

Skin Health Institute Inc - Probity - PPDS

Carlton, Victoria, Australia

Alfred Health

Parkville, Victoria, Australia

Western Health - Sunshine Hospital

Parkville, Victoria, Australia

Medical Center Unimed EOOD-Sevlievo

Sevlievo, Gabrovo, Bulgaria

Medical Center Asklepii OOD

Dupnitsa, Kyustendil, Bulgaria

Diagnostic and Consulting Center Aleksandrovska EOOD

Sofia, Sofia-Grad, Bulgaria

Diagnostic Consultative Centre - Focus-5 - LZIP EOOD

Sofia, Sofia-Grad, Bulgaria

Medical Center Hera EOOD-Sofia

Sofia, Sofia-Grad, Bulgaria

Diagnostic Consultative Center XXVIII - Sofia - EOOD

Sofia, Sofia-Grad, Bulgaria

Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia

Sofia, Sofia-Grad, Bulgaria

MC Comac Medical

Sofia, Sofia-Grad, Bulgaria

Multiprofile Hospital For Active Treatment Dr Tota Venkova

Gabrovo, Bulgaria

Diagnostic Consultative Center Sveti

Haskovo, Bulgaria

Medical Center Medconsult Pleven OOD

Pleven, Bulgaria

Beacon Dermatology - Probity

Calgary, Alberta, Canada

Dermatology Research Institute, Inc.

Calgary, Alberta, Canada

Alberta DermaSurgery Centre - Probity

Edmonton, Alberta, Canada

VIDA Dermatology - Probity

Edmonton, Alberta, Canada

Care Clinic

Red Deer, Alberta, Canada

Enverus Medical Research - Probity

Surrey, British Columbia, Canada

Wiseman Dermatology Research Inc.

Winnipeg, Manitoba, Canada

Karma Clinical Trials

St. John's, Newfoundland and Labrador, Canada

CCA Medical Research - Probity

Ajax, Ontario, Canada

SimcoDerm Medical and Surgical Dermatology Centre - Probity

Barrie, Ontario, Canada

Kingsway Clinical Research - Probity

Etobicoke, Ontario, Canada

Guelph Dermatology Research - Probity

Guelph, Ontario, Canada

Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity

Hamilton, Ontario, Canada

Dermatrials Research

Hamilton, Ontario, Canada

Mediprobe Research Inc

London, Ontario, Canada

DermEffects

London, Ontario, Canada

Lynderm Research Inc - Probity

Markham, Ontario, Canada

DermEdge Research - Probity

Mississauga, Ontario, Canada

Dr. S. K. Siddha Medicine Professional Corporation | Newmarket, Canada

Newmarket, Ontario, Canada

North Bay Dermatology Center - Probity

North Bay, Ontario, Canada

The Centre for Clinical Trials Inc.

Oakville, Ontario, Canada

Skin Centre for Dermatology

Peterborough, Ontario, Canada

The Centre For Dermatology

Richmond Hill, Ontario, Canada

North York Research Inc. - Probity

Toronto, Ontario, Canada

Canadian Dermatology Centre - Probity

Toronto, Ontario, Canada

Toronto Research Centre

Toronto, Ontario, Canada

Toronto Research Centre - Probity

Toronto, Ontario, Canada

Alliance Clinical Trials

Waterloo, Ontario, Canada

XLR8 Medical Research

Windsor, Ontario, Canada

Siena Medical Research Corporation

Montreal, Quebec, Canada

Skinsense Medical Research - Probity

Saskatoon, Saskatchewan, Canada

Peking University People's Hospital

Beijing, Beijing Municipality, China

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Peking University Third Hospital

Beijing, Beijing Municipality, China

Beijing Tongren Hospital, Capital Medical University

Beijing, Beijing Municipality, China

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Dermatology Hospital of Southern Medical University

Guangzhou, Guangdong, China

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

The First Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST)

Wuhan, Hubei, China

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

Wuhan, Hubei, China

Renmin Hospital of Wuhan University

Wuhan, Hubei, China

Affiliated Hospital of Jiangsu University

Zhenjiang, Jiangsu, China

Huashan Hospital Fudan University - PPDS

Shanghai, Minhang District, China

General Hospital of Ningxia Medical University

Yinchuan, Ningxia Hui, China

The 2nd Hospital of Xi'An Jiaotong University

Xi'an, Shan'xi, China

Shandong Provincial Hospital

Jinan, Shandong, China

Shanghai Skin Disease Hospital

Shanghai, Shanghai Municipality, China

First Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

Sir Run Run Shaw Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

The 1st Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

The University of Hong Kong - Shenzhen Hospital

Shenzhen, China

Dermamedica, s.r.o. - Kozni Ambulance Nachod

Náchod, Královéhradecký kraj, Czechia

Nemocnice AGEL Novy Jicin a.s

Nový Jičín, Moravskoslezský kraj, Czechia

CCR Ostrava s.r.o.

Ostrava, Moravskoslezský kraj, Czechia

Dermskin s.r.o

Olomouc, Olomoucký kraj, Czechia

Pratia Pardubice a.s. - PRATIA - PPDS

Pardubice, Pardubický kraj, Czechia

Pratia Brno s.r.o. - PRATIA - PPDS

Brno, South Moravian, Czechia

CLINTRIAL s.r.o.

Prague, Czechia

Prof. MUDr. Petr Arenberger, DrSc. - CRC - PPDS

Prague, Czechia

Praglandia

Prague, Czechia

Fakultni nemocnice Kralovske Vinohrady

Prague, Czechia

Office of Mireille Ruer-Mulard, MD

Martigues, Paca, France

Centre Hospitalier Le Mans

Le Mans, Sarthe, France

Hopital Charles Nicolle-1 Rue de Germont

Rouen, France

Centre Hospitalier Universitaire de Saint Etienne

Saint-Etienne, France

Hautarztpraxis Mahlow

Blankenfelde-Mahlow, Brandenburg, Germany

Fachklinik Bad Bentheim

Bad Bentheim, Lower Saxony, Germany

Klinikum Oldenburg

Oldenburg, Lower Saxony, Germany

Klinische Forschung Dresden Gmbh

Dresden, Saxony, Germany

Praxis fur Dermatologie and Venerologie

Dresden, Saxony, Germany

SRH Wald-Klinikum Gera GmbH

Gera, Thuringia, Germany

Dermatologikum Hamburg

Hamburg, Germany

Allergo-Derm Bakos Kft.

Szolnok, Jász-Nagykun-Szolnok, Hungary

Somogy Megyei Kaposi Mór Oktató Kórház

Kaposvár, Somogy County, Hungary

Markusovszky Egyetemi Oktatókórház

Szombathely, Vas County, Hungary

Debreceni Egyetem

Debrecen, Hungary

Rabin Medical Center - PPDS

Petah Tikva, Israel

Chaim Sheba Medical Center

Ramat Gan, Israel

IRCCS Istituto Clinico Humanitas

Rozzano, Milano, Italy

Presidio Ospedaliero Gaspare Rodolico

Catania, Sicily, Italy

Azienda Usl Toscana Centro - Firenze

Florence, Tuscany, Italy

Nagoya City University Hospital

Nagoya, Aichi-ken, Japan

Hino Dermatology Clinic

Fukutsu-shi, Fukuoka, Japan

Takagi Dermatological Clinic

Obihiro-Shi, Hokkaidô, Japan

JR Sapporo Hospital

Sapporo, Hokkaidô, Japan

Medical Corporation Kojinkai Sapporo Skin Clinic

Sapporo, Hokkaidô, Japan

Fukuoka University Hospital

Fukuoka, Hukuoka, Japan

Nippon Life Hospital

Osaka, Osaka, Japan

Seikoukai Omi Medical Center

Kusatsu-shi, Shiga, Japan

Jichi Medical University Hospital

Shimotsuke-shi, Tochigi, Japan

St. Luke's International Hospital

Chuo-ku, Tokyo, Japan

Tokyo Teishin Hospital

Sumida-Ku, Tokyo, Japan

Medical Corporation Jitai-kai Tachikawa Dermatology Clinic

Tachikawa-shi, Tokyo, Japan

JCHO Tokyo Yamate Medical Center

Shinjuku-ku, Tokyo-To, Japan

Shirasaki Dermatology Clinic

Takaoka-shi, Toyama, Japan

Ohyama Dermatology Clinic

Kumamoto, Japan

Tokyo Medical University Hospital

Tokyo, Japan

Dermatology and Ophthalmology Kume Clinic

Sakaishi, Ôsaka, Japan

Smite Aija medical practice in dermatology, venerology

Talsi, Talsu Aprinkis, Latvia

Semigallia

Kuldīga, Latvia

Riga 1st Hospital

Riga, Latvia

Aesthetic dermatology clinic of prof. J. Kisis

Riga, Latvia

Health Center 4-1 Grebenscikova Str

Riga, Latvia

Veseliba un estetika Ltd.

Riga, Latvia

Outpatient Clinic Adoria

Riga, Latvia

Health Center 4-Skanstes iela 50

Riga, Latvia

AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu

Poznan, Greater Poland Voivodeship, Poland

Twoja Przychodnia PCM

Poznan, Greater Poland Voivodeship, Poland

Centrum Medyczne ALL-MED

Krakow, Lesser Poland Voivodeship, Poland

Pratia MCM Krakow

Krakow, Lesser Poland Voivodeship, Poland

Krakowskie Centrum Medyczne Sp. z o.o.

Krakow, Lesser Poland Voivodeship, Poland

Centrum Medyczne Katowice - PRATIA

Katowice, Lower Silesian Voivodeship, Poland

Globe Badania Kliniczne Spolka z o.o. - Klodzko

Kłodzko, Lower Silesian Voivodeship, Poland

Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.p

Wroclaw, Lower Silesian Voivodeship, Poland

Clinical Best Solutions Sp. z o.o. S.K.

Lublin, Lublin Voivodeship, Poland

Luxderm Specjalistyczny Gabinet Dermatologiczny Dorota Krasowska

Lublin, Lublin Voivodeship, Poland

Centrum Terapii Współczesnej J.M. Jasnorzewska S.K.A.

Lódz, Lódzkie, Poland

Rheumatology Clinic NZOZ Lecznica MAK-MED

Nadarzyn, Masovian Voivodeship, Poland

ETG Siedlce - PPDS

Siedlce, Masovian Voivodeship, Poland

RCMed Oddzial Sochaczew

Sochaczew, Masovian Voivodeship, Poland

Clinical Best Solutions Sp. z o.o. S.K.